Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Three-arm Parallel-Group, 12-Month Study to Evaluate the Safety and Efficacy of ALS-L1023 Administered in Combination with Ranibizumab in Patients with Neovascular (wet) Age-Related Macular Degeneration (AMD) (McEye Study)

Trial Profile

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Three-arm Parallel-Group, 12-Month Study to Evaluate the Safety and Efficacy of ALS-L1023 Administered in Combination with Ranibizumab in Patients with Neovascular (wet) Age-Related Macular Degeneration (AMD) (McEye Study)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALS L1023 (Primary) ; Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms McEye Study
  • Sponsors AngioLab Inc
  • Most Recent Events

    • 08 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 19 Nov 2018 Planned End Date changed from 1 Dec 2020 to 30 Jul 2021.
    • 19 Nov 2018 Planned primary completion date changed from 1 Oct 2020 to 31 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top